Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$35.50

-1.97 (-5.26%)

18:03
11/28/16
11/28
18:03
11/28/16
18:03

Blueprint Medicines 'encouraged' by early Phase 1 BLU-554 trial data

Blueprint Medicines Corporation announced data from its ongoing Phase 1 trial evaluating BLU-554, an investigational medicine for the treatment of advanced hepatocellular carcinoma. Blueprint Medicines is developing BLU-554 as a potent, highly selective inhibitor of fibroblast growth factor receptor 4. The data are being presented on Tuesday, November 29, 2016, at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. "We are very encouraged to see early anti-tumor activity in patients with confirmed FGF19 overexpression and consistent evidence of FGFR4 pathway modulation during the dose escalation part of this first-in-human clinical trial," said Andy Boral, M.D., Chief Medical Officer of Blueprint Medicines. "Now that we have demonstrated proof-of-concept, determined the maximum tolerated dose, and implemented FGF19 biomarker screening globally, we can move rapidly to enroll patients in the expansion part of the study to more fully evaluate the activity of BLU-554 in patients with advanced HCC." BLU-554 was evaluated in the dose escalation stage of a Phase 1 clinical trial in patients with advanced HCC. As of the data cutoff date of November 7, 2016, 25 patients had been treated in the dose escalation portion of the Phase 1 clinical trial at five dose levels, with the majority of patients having previously received sorafenib. The study was designed to retroactively assess patient biopsies for FGFR4 pathway activation after enrollment by evaluating levels of FGF19, the protein that activates FGFR4, using an investigational immunohistochemistry assay. Prospective screening of patients with the investigational IHC assay was implemented during dose escalation, enabling enrollment of enrichment patients with confirmed FGF19 overexpression which resulted in a larger number than anticipated of biomarker positive patients being enrolled. Blueprint Medicines has initiated the expansion portion of the Phase 1 clinical trial, and enrollment is ongoing. Pharmacokinetic data across all dose levels showed rapid oral absorption, a mean half-life of approximately ten hours, and exposure in the expected therapeutic range based on HCC xenograft models. Blueprint Medicines has initiated enrollment of the biomarker-selected expansion cohorts at the maximum tolerated dose of 600 mg QD. In the expansion, patients will be prospectively evaluated for tumor expression of FGF19 using an investigational IHC assay. We plan to enroll approximately 45 patients in three subsets. Two subsets of patients will be selected to have tumors that overexpress FGF19, which indicates autocrine physiology, where FGF19 is produced by the tumor cells in the liver. One of the patient subsets with tumors that overexpress FGF19 will also have FGF19 gene amplification. The third subset of patients will be selected to have tumor FGF19 expression less than 1% by the IHC assay, which indicates normal endocrine physiology, where FGF19 is produced by the intestine.

  • 29

    Nov

  • 01

    Dec

  • 03

    Dec

  • 05

    Dec

BPMC Blueprint Medicines
$35.50

-1.97 (-5.26%)

05/27/16
RAJA
05/27/16
INITIATION
Target $23
RAJA
Outperform
Blueprint Medicines initiated with an Outperform at Raymond James
Raymond James analyst Chris Raymond initiated Blueprint Medicines with an Outperform rating and $23 price target. The analyst thinks Blueprint's unique kinase inhibitor discovery platform is well-positioned to generate novel compounds for years to come. Coupling this with a clinical stage pipeline that remains wholly-owned, key proof-of-concept data for two products,BLU-285 and BLU-554, in three different indications by year end 2015, and a valuation offering favorable risk/reward.
08/05/16
ADAM
08/05/16
INITIATION
Target $26
ADAM
Buy
Blueprint Medicines initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Blueprint Medicines with a Buy and $26 price target.
11/11/16
ADAM
11/11/16
NO CHANGE
Target $35
ADAM
Buy
Blueprint Medicines price target raised to $35 from $26 at Canaccord
Canaccord analyst Arlinda Lee raised her target on Blueprint Medicines to $35 from $26 following company updates on its pipeline of novel, rationally designed, target kinase inhibitors. The analyst increased her probability of success for the company's three programs to 25% from 20% and maintained her Buy rating on Blueprint Medicines shares.

TODAY'S FREE FLY STORIES

NUVA

NuVasive

$51.99

-1.34 (-2.51%)

20:43
01/16/18
01/16
20:43
01/16/18
20:43
Downgrade
NuVasive rating change at Wells Fargo »

NuVasive downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

20:38
01/16/18
01/16
20:38
01/16/18
20:38
Recommendations
Juno Therapeutics, Celgene, Acquired by GILD 9/17, Gilead analyst commentary at Citi »

Juno could be worth $110…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

KITE

Acquired by GILD 9/17

GILD

Gilead

$80.25

1.23 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 12

    Feb

  • 16

    Feb

  • 25

    Mar

SNP

Sinopec

$83.07

-1 (-1.19%)

20:35
01/16/18
01/16
20:35
01/16/18
20:35
Upgrade
Sinopec rating change at Jefferies »

Sinopec upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

20:34
01/16/18
01/16
20:34
01/16/18
20:34
Downgrade
Shell Midstream rating change at Stifel »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

UNH

UnitedHealth

$232.90

4.26 (1.86%)

20:31
01/16/18
01/16
20:31
01/16/18
20:31
Recommendations
UnitedHealth analyst commentary at Piper Jaffray »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

AVXS

AveXis

$105.01

-12.49 (-10.63%)

20:31
01/16/18
01/16
20:31
01/16/18
20:31
Syndicate
AveXis 3.921M share Secondary priced at $102.00 »

Goldman Sachs, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OZRK

Bank of the Ozarks

$52.23

-0.24 (-0.46%)

20:26
01/16/18
01/16
20:26
01/16/18
20:26
Downgrade
Bank of the Ozarks rating change at Keefe Bruyette »

Bank of the Ozarks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 30

    Jan

WP

Worldpay

$78.26

0.66 (0.85%)

, VNTV

Symbol changed to WP

20:25
01/16/18
01/16
20:25
01/16/18
20:25
Initiation
Worldpay, Symbol changed to WP initiated at Goldman Sachs »

Worldpay reinstated with…

WP

Worldpay

$78.26

0.66 (0.85%)

VNTV

Symbol changed to WP

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.24

0.05 (0.16%)

, GS

Goldman Sachs

$258.46

1.43 (0.56%)

20:25
01/16/18
01/16
20:25
01/16/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$31.24

0.05 (0.16%)

GS

Goldman Sachs

$258.46

1.43 (0.56%)

USB

U.S. Bancorp

$57.17

0.19 (0.33%)

FAST

Fastenal

$55.44

-0.15 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

  • 15

    Feb

C

Citi

$77.11

0.27 (0.35%)

20:20
01/16/18
01/16
20:20
01/16/18
20:20
Downgrade
Citi rating change at Keefe Bruyette »

Citi downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 18

    Jan

  • 24

    Jan

O

Realty Income

$52.94

0.22 (0.42%)

19:12
01/16/18
01/16
19:12
01/16/18
19:12
Hot Stocks
Realty Income raises monthly dividend to 21.9c per share from 21.25c »

Realty Income announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:05
01/16/18
01/16
19:05
01/16/18
19:05
Hot Stocks
New Gold sees FY18 gold production 525,000-595,000 ounces »

Sees FY18 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:04
01/16/18
01/16
19:04
01/16/18
19:04
Hot Stocks
New Gold reports Q4 gold production 154,446 ounces »

Reports Q4 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:04
01/16/18
01/16
19:04
01/16/18
19:04
Hot Stocks
New Gold reports FY17 gold production 430,864 ounces »

Reports FY17 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$80.42

-0.12 (-0.15%)

18:50
01/16/18
01/16
18:50
01/16/18
18:50
Earnings
PayPal sees FY18 revenue $15B-$15.25B, consensus $15.35B »

Backs FY18 TPV Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

CE

Celanese

$109.67

-1.67 (-1.50%)

18:32
01/16/18
01/16
18:32
01/16/18
18:32
Hot Stocks
Celanese increases the price of low density polyethylene to 4c »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

RIG

Transocean

$11.47

-0.73 (-5.98%)

18:27
01/16/18
01/16
18:27
01/16/18
18:27
Hot Stocks
Transocean shareholders show 'overwhelming support' for Songa transaction »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

WMT

Walmart

$100.69

-0.18 (-0.18%)

18:13
01/16/18
01/16
18:13
01/16/18
18:13
Periodicals
Wal-Mart COO to be named international CEO, Reuters says »

Wal-Mart Stores COO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CME

CME Group

$152.20

-0.53 (-0.35%)

18:05
01/16/18
01/16
18:05
01/16/18
18:05
Hot Stocks
CME reaches daily trading volume record for Henry Hub Nat Gas futures on Jan 12 »

CME Group announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 01

    Feb

CE

Celanese

$109.67

-1.67 (-1.50%)

18:02
01/16/18
01/16
18:02
01/16/18
18:02
Hot Stocks
Celanese announces price increases for engineered materials polymer products »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SRC

Spirit Realty

$8.07

-0.03 (-0.37%)

17:46
01/16/18
01/16
17:46
01/16/18
17:46
Hot Stocks
Spirit Realty funds $35M into Shopko master lease »

Spirit Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

17:45
01/16/18
01/16
17:45
01/16/18
17:45
Conference/Events
Nutanix management to meet with Piper Jaffray »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

17:41
01/16/18
01/16
17:41
01/16/18
17:41
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Juno Therapeutics…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

NEWA

Newater Technology

$15.80

2.8 (21.54%)

VRS

Verso

$17.00

0.06 (0.35%)

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

IPSEY

Ipsen

RNST

Renasant

$43.86

0.15 (0.34%)

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

CSX

CSX

$58.13

-1.12 (-1.89%)

ATEN

A10 Networks

$7.31

-0.27 (-3.56%)

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

HIVE

Aerohive

$5.70

-0.19 (-3.23%)

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

XON

Intrexon

$13.77

-0.94 (-6.39%)

BOOT

Boot Barn

$19.10

-0.15 (-0.78%)

F

Ford

$13.10

-0.13 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 26

    Feb

  • 01

    Mar

  • 25

    Mar

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

NRZ

New Residential

$17.63

-0.11 (-0.62%)

17:35
01/16/18
01/16
17:35
01/16/18
17:35
Earnings
Breaking Earnings news story on New Residential »

New Residential sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

17:30
01/16/18
01/16
17:30
01/16/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Exelixis »

Exelixis up 3.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.